Dark Canyon Laboratories Plans Phase 2 Clinical Trial

Robarts Clinical Trials, Inc. has been retained by Dark Canyon Labs to conduct a Phase 2 Clinical Trial beginning late 2016.  The trial will enroll approximately 357 patients across 7 investigative sites. This randomized, investigator-blinded, non-inferiority study will compare the safety and efficacy of DCL-101 to the current gold standard of colonoscopy preps, GoLYTELY®.  Additional data on tolerability and patient preferences will be collected.  

A subsidiary of the University of Western Ontario, Robarts is a global academic Clinical Research Organization (CRO) that provides a broad range of clinical research services to pharmaceutical and biotechnology companies, government agencies and academic investigators.

Dark Canyon Labs is especially excited to be working with Robarts because they are globally recognized for their innovation and specialized expertise in the processing and centralized review of GI endoscopic video recordings with Central Image Management Solutions (CIMS).